Cancer A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma Tony Mok (2002)
Oncology Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer Tony Mok (2005)
J Thorac Oncol Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer Tony Mok (2006)
Lancet Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Tony Mok (2008)
Invest New Drugs A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells Tony Mok (2008)
J Clin Oncol Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer Tony Mok (2009)
J Clin Oncol Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial Tony Mok (2010)
J Clin Oncol Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) Tony Mok (2011)
N Engl J Med Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma Tony Mok (2011)
Ann Oncol A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer Tony Mok (2011)
BMC Cancer INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer Tony Mok (2011)
Asia Pac J Clin Oncol Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in lung trial Tony Mok (2011)
J Thorac Oncol Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer Tony Mok (2012)
Clin Lung Cancer Treatment rationale study design for the MetLung Trial: A randomized, double-blind phase III study of Onartuzumab (MetMAb) in combination with Erlotinib versus Erlotinib alone in patients who have received standard chemotherapy for stage IIIB or IV Met-positive non-small-cell lung cancer Tony Mok (2012)
Asia Pac J Clin Oncol Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from China Tony Mok (2012)
N Engl J Med Crizotinib versus chemotherapy in advanced ALK-positive lung cancer Tony Mok (2013)
Lancet Oncol Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial Tony Mok (2013)
J Clin Oncol Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations Tony Mok (2013)
J Clin Oncol Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations Tony Mok (2013)
Lung Cancer Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study Tony Mok (2013)
N Engl J Med First-line crizotinib versus chemotherapy in ALK-positive lung cancer Tony Mok (2014)
Lancet Oncol Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial Tony Mok (2014)
Lancet Oncol Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial Tony Mok (2014)
J Clin Oncol Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer Tony Mok (2014)
Ann Oncol Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer Tony Mok (2014)
J Thorac Oncol A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015) Tony Mok (2014)
Eur J Cancer First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial Tony Mok (2014)
Lung Cancer Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer Tony Mok (2014)
Lung Cancer Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia study (IPASS) Tony Mok (2014)
Lancet Oncol Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 Tony Mok (2015)
Lancet Oncol Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials Tony Mok (2015)
Lancet Oncol Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial Tony Mok (2015)
J Thorac Oncol EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey Tony Mok (2015)
J Thorac Oncol Monotherapy administration of Sorafenib in patients with non-small cell lung cancer (MISSION) trial: A phase III, multicenter, placebo-controlled trial of Sorafenib in patients with relapsed or refractory predominantly nonsquamous non-small-cell lung cancer after 2 or 3 previous treatment regimens Tony Mok (2015)
Clin Cancer Res Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated Erlotinib and chemotherapy Tony Mok (2015)
Lancet Oncol Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial Tony Mok (2016)
J Clin Oncol Multicenter phase II study of whole-body and intracranial activity with Ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and Crizotinib: Results from ASCEND-2 Tony Mok (2016)
J Clin Oncol PROCLAIM: Randomized phase III trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer Tony Mok (2016)
J Clin Oncol Intracranial efficacy of Crizotinib versus Chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: Results from PROFILE 1014 Tony Mok (2016)
JAMA Oncol First-line Erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with Epidermal Growth Factor Receptor mutation-positive non-small-cell lung cancer: The ASPIRATION study Tony Mok (2016)
J Thorac Oncol First-line Afatinib versus Chemotherapy in patients with non-small cell lung cancer and common Epidermal Growth Factor Receptor gene mutations and brain metastases Tony Mok (2016)
J Thorac Oncol A randomized phase 2 study comparing the combination of Ficlatuzumab and Gefitinib with Gefitinib alone in Asian patients with advanced stage pulmonary adenocarcinoma Tony Mok (2016)
J Thorac Oncol First-line Pemetrexed plus Cisplatin followed by Gefitinib maintenance therapy versus Gefitinib monotherapy in East Asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study Tony Mok (2016)
Lung Cancer Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer Tony Mok (2016)
N Engl J Med Osimertinib or Platinum-Pemetrexed in EGFR T790M-positive lung cancer Tony Mok (2017)
N Engl J Med Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung cancer Tony Mok (2017)
Lancet Oncol Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial Tony Mok (2017)
Lancet Oncol Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial Tony Mok (2017)
J Clin Oncol Results from the phase III randomized trial of Onartuzumab plus Erlotinib versus Erlotinib in previouslytreated stage IIIB or IV non-small-cell lung cancer: METLung Tony Mok (2017)
J Clin Oncol Targeting RET in patients with RET-rearranged lung cancers: Results from the global, multicenter RET registry Tony Mok (2017)
J Clin Oncol Gefitinib plus Chemotherapy versus Chemotherapy in Epidermal Growth Factor Receptor mutation-positive non-small-cell lung cancer resistant to first-line Gefitinib (IMPRESS): Overall survival and biomarker Analyses Tony Mok (2017)
Ann Oncol Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer) Tony Mok (2017)
ESMO Open Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer Tony Mok (2017)
Br J Cancer EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6 Tony Mok (2017)
Lung Cancer Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC Tony Mok (2017)
N Engl J Med First-line Atezolizumab plus Chemotherapy in extensive-stage small-cell lung cancer Tony Mok (2018)
J Clin Oncol CNS efficacy of Osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: Data from a randomized phase III trial (AURA3) Tony Mok (2018)
J Clin Oncol Improvement in overall survival in a randomized study that compared Dacomitinib with Gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations Tony Mok (2018)
J Clin Oncol Patient-reported symptoms and impact of treatment with Osimertinib versus Chemotherapy in advanced non-small-celllung cancer: The AURA3 trial Tony Mok (2018)
J Clin Oncol Final overall survival analysis from a study comparing first-line Crizotinib versus Chemotherapy in ALK-mutation-positive non-small-cell lung cancer Tony Mok (2018)
J Thorac Oncol Results of PROFILE 1029, a phase III comparison of first-line Crizotinib versus Chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer Tony Mok (2018)
Lung Cancer Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies Tony Mok (2018)
Clin Lung Cancer Afatinib as first-line treatment of older patients with EGFR mutation-positive non-small-cell lung cancer: Subgroup analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 trials Tony Mok (2018)
Patient Does EGFR mutation type influence patient-reported outcomes in patients with advanced EGFR mutation-positive non-small-cell lung cancer? Analysis of two large, phase III studies comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6) Tony Mok (2018)
Lancet Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Tony Mok (2019)
Lancet Respir Med Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial Tony Mok (2019)
J Thorac Oncol Nivolumab versus Docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial Tony Mok (2019)
J Thorac Oncol Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of Alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study Tony Mok (2019)
J Cancer Res Clin Oncol First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression Tony Mok (2019)
N Engl J Med First-line Lorlatinib or Crizotinib in advanced ALK-positive lung cancer Tony Mok (2020)
Nat Med Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer Tony Mok (2020)
Ann Oncol Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis Tony Mok (2020)
J Thorac Oncol Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: The AURA leptomeningeal metastases analysis Tony Mok (2020)
J Thorac Oncol Final overall survival and other efficacy and safety results from ASCEND-3: Phase II study of Ceritinib in ALKi-naive patients with ALK-rearranged NSCLC Tony Mok (2020)
Cancer Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer Tony Mok (2020)
Int J Cancer Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China study Tony Mok (2020)
Front Oncol The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050 Tony Mok (2020)
Lung Cancer Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078) Tony Mok (2020)
Lung Cancer ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI Tony Mok (2020)
J Clin Oncol Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with Atezolizumab, Carboplatin, and Etoposide (IMpower133) Tony Mok (2021)
J Thorac Oncol Outcomes according to ALK status determined by central immunohistochemistry or fluorescencein situ hybridization in patients with ALK-positive NSCLC enrolled in the phase 3 ALEX study Tony Mok (2021)
Anticancer Drugs Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer Tony Mok (2002)
J Clin Oncol Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA Tony Mok (2004)
J Natl Cancer Inst A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma Tony Mok (2005)
Ann Oncol A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity Tony Mok (2007)
J Vasc Interv Radiol Transarterial ethanol ablation of hepatocellular carcinoma with lipiodol ethanol mixture: phase II study Tony Mok (2008)
Cancer Chemother Pharmacol A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy Tony Mok (2008)
Invest New Drugs An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma Tony Mok (2012)
Radiology Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization Tony Mok (2014)
Cancer A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma Tony Mok (2017)